Skip to main content

This website uses cookies. By continuing to use this website, you consent to our use of these cookies. Read more about our use of cookies.

I agree
Sobi logotype

Main navigation (without target group)

  • About Sobi
    • Who We Are
    • Leadership
    • Rare Diseases
    • Responsibility
  • Countries and Products
    • United States
    • Canada
  • Investigator Sponsored Studies
    • Transparency and Integrity
    • Submission Requirements
    • Review Process
    • Areas of Interest
  • News
  • Careers
  • Contact Us

Breadcrumb

  1. Home
  2. News

News archive

A news archive from Sobi in North America

Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

06/15/2020 - 16:06

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine

05/07/2020 - 08:28

Sobi publishes report for the first quarter 2020

05/05/2020 - 13:24
  • Load More
Smiling woman

Global News

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine.

More Global News

Filter by Year

2020
2019
2018
2017
2016
2015
2014

News archive

A news archive from Sobi in North America

Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

06/15/2020 - 16:06

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine

05/07/2020 - 08:28

Sobi publishes report for the first quarter 2020

05/05/2020 - 13:24
  • Load More
Smiling woman

Global News

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine.

More Global News

Filter by Year

2020
2019
2018
2017
2016
2015
2014

Footer Menu

  • Cookies
  • Terms of use

Copyright Notice:  © Sobi, Inc. 2018

This site contains medical information that is intended for residents of the United States and Canada only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy 

Sobi United States
+1 781-786-7370
890 Winter Street
Waltham, MA 02451, USA

Sobi Canada
+1 289-291-3852
1155 North Service Rd. West, Unit #11,
Oakville, Ontario, Canada L6M 3E3